Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.62 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL154439 | 0.81 | MAPT (0.64) | CYP2A6CHRNA7SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL20932892 | 0.81 | LTA4H (0.51) | CYP2A6CHRNA7SMN1; SMN2MAPTTP53 | |
| SCHEMBL27320554 | 0.80 | CYP2A6 (0.44) | CYP2A6SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL8821145 | 0.78 | CYP2A6 (0.54) | CYP2A6CHRNA7SMN1; SMN2CA1CA2 | |
| SCHEMBL2248829 | 0.77 | CYP2A6 (1.00) | CYP2A6CHRNA7SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL1304400 | 0.76 | CYP2A6 (0.62) | CYP2A6CHRNA7SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL27429824 | 0.76 | CYP2A6 (0.56) | CYP2A6CHRNA7SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL14925170 | 0.76 | CYP2A6 (0.56) | CYP2A6CHRNA7SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL1567143 | 0.75 | CYP2A6 (0.67) | CYP2A6CHRNA7SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL2537423 | 0.75 | CYP2A6 (0.67) | CYP2A6CHRNA7SMN1; SMN2CRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | Smilebiotek Zhuhai Limited (CN) | 2024-06-25 | — | — | US | disclosed |
| WO-2022262310-A1 | METHOD FOR SYNTHESIZING BTBF AROMATIC AMINE DERIVATIVES | 广东阿格蕾雅光电材料有限公司 | 2022-12-22 | — | — | WO | disclosed |
| US-6653328-B1 | Post-menopausal syndrome; estrogen dependent diseases | ELI LILLY AND COMPANY | 2003-11-25 | — | — | US | disclosed |
| US-6653328-B1 | Post-menopausal syndrome; estrogen dependent diseases | ELI LILLY AND COMPANY | 2003-11-25 | — | — | US | disclosed |
| US-6653328-B1 | Post-menopausal syndrome; estrogen dependent diseases | ELI LILLY AND COMPANY | 2003-11-25 | — | — | US | disclosed |
| EP-0731101-B1 | 3-Benzyl-benzothiophenes | LILLY CO ELI (US) | 2003-06-11 | — | — | EP | disclosed |
| EP-0731101-B1 | 3-Benzyl-benzothiophenes | LILLY CO ELI (US) | 2003-06-11 | — | — | EP | disclosed |
| US-6417199-B1 | 3-benzyl-benzothiophenes | ELI LILLY AND COMPANY | 2002-07-09 | — | — | US | disclosed |
| US-6417199-B1 | 3-benzyl-benzothiophenes | ELI LILLY AND COMPANY | 2002-07-09 | — | — | US | disclosed |
| US-6417199-B1 | 3-benzyl-benzothiophenes | ELI LILLY AND COMPANY | 2002-07-09 | — | — | US | disclosed |
| EP-1077970-A1 | 11-ARYL-BENZO(B)NAPHTHO(2,3-D)FURANS AND 11-ARYL-BENZO(B)NAPHTHO(2,3-D)THIOPHENES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6110962-A | FOR TREATING INSULIN RESISTANCE, TYPE II DIABETES, HYPERGLYCEMIA, MODULATING INSULIN LEVELS IN MAMMALS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-08-29 | — | — | US | disclosed |
| WO-1999058521-A1 | 11-ARYL-BENZO[B]NAPHTHO[2,3-D]FURANS AND 11-ARYL-BENZO[B]NAPHTHO[2,3-D]THIOPHENES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-18 | — | — | WO | disclosed |
| EP-0731101-A1 | 3-Benzyl-benzothiophenes | ELI LILLY AND COMPANY (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0731101-A1 | 3-Benzyl-benzothiophenes | ELI LILLY AND COMPANY (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0731101-A1 | 3-Benzyl-benzothiophenes | ELI LILLY AND COMPANY (US) | 1996-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | MB, MYOC, PDE6A | CYP2A6 4171/4885CHRNA7 2983/4885SMN1; SMN2 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.